Liver transplant, toxoplasmosis and kidney stones: connecting the dots

Harini Bejjanki, Olanrewaju A Olaoye, Alfonso H Santos, Abhilash Koratala

1Department of Medicine, University of Florida, Gainesville, Florida, USA
2Department of Nephrology, University of Florida College of Medicine, Gainesville, Florida, USA

Correspondence to Dr Abhilash Koratala, akoratsla@ufl.edu

Accepted 28 January 2019

DESCRIPTION

A 62-year-old woman with a history of orthotopic liver transplantation for cirrhosis secondary to auto-immune hepatitis 3 months prior, presented with fever and new-onset seizures. Her maintenance immunosuppressive therapy included mycophenolate mofetil 500 mg twice a day, tacrolimus 1 mg twice a day and prednisone 5 mg per day. Aerosolised pentamidine was being used for post-transplant Pneumocystis jirovecii prophylaxis instead of the standard therapy with trimethoprim-sulfamethoxazole because of recurrent episodes of serum creatinine elevation and hyperkalaemia in the immediate post-operative period. MRI of the brain demonstrated approximately 1.8×1.9×2.2 cm ring enhancing lesion in the right posterior frontal lobe with significant surrounding vasogenic oedema figure 1. Cerebrospinal Fluid (CSF) analysis showed lymphocytic pleocytosis but was negative CSF toxoplasma polymerase chain reaction. Due to high clinical suspicion, ring enhancing lesion on MRI and positive toxoplasma serum IgG, she was diagnosed with cerebral toxoplasmosis and initiated on sulfadiazine 1000 mg every 6 hours, Pyrimethamine and Leucovorin.1 2 Repeat MRI of the brain 3 weeks after initiation of Sulfadiazine showed improvement in the size of the lesion and vasogenic oedema suggesting response to treatment and therefore, biopsy was not pursued. Around the same time, the patient developed gross haematuria, flank pain and mild acute Kidney Injury with a serum creatinine 1.3 mg/dL (baseline ~0.9). A renal sonogram

Figure 2 (A) Renal sonogram 3 weeks after starting sulfadiazine demonstrating nephrolithiasis (arrows). Acoustic shadowing (asterisks) refers to the black area seen beyond the stones (structures that do not transmit ultrasound waves). (B) On doppler mode, stones exhibit twinkling sign, which is a rapidly alternating focus of colour Doppler signals mimicking turbulent flow (arrows). This sign is helpful when the shadowing is not apparent. LT, left; RT, right.

Learning points

► Toxoplasma polymerase chain reaction testing in the Cerebrospinal Fluid has high specificity but variable sensitivity depending on the primer used. Therefore, it would be prudent to proceed with the treatment when the suspicion for cerebral toxoplasmosis is high.
► Aerosolised pentamidine, which our patient was receiving is not recommended for Toxoplasma prophylaxis. The data on prevention of toxoplasmosis is sparse and trimethoprim-sulfamethoxazole at a dose of one double-strength tablet three times/week is thought to be sufficient for both Pneumocystis and Toxoplasma prevention.
► Sulfonamide antibiotics such as sulfadiazine are relatively insoluble in acid urine, especially when used in high doses to treat toxoplasmosis, which may lead to crystal-induced acute kidney injury (crystalline nephropathy) and/or nephrolithiasis from intrarenal drug precipitation. Alkalisation of the urine to a pH more than 7.15 increases sulfadiazine solubility considerably.
was obtained which showed non-obstructing bilateral renal stones with the classic acoustic shadowing and twinkling sign\(^1\) [figure 2]. She did not have known history of nephrolithiasis and review of CT of the abdomen prior to transplant confirmed the same. Urinalysis was significant for a pH of 5, 16 red blood cells per high power field and multiple hyaline casts. These findings were attributed to sulfadiazine-induced nephrolithiasis and the drug was transitioned to atovaquone.\(^\text{4}\text{–}6\) She was started on oral alkali supplementation to alkalise the urine and her symptoms resolved in less than a week. A repeat renal sonogram obtained 6 months later demonstrated complete resolution of stones, retrospectively confirming the diagnosis of drug-induced nephrolithiasis.

**Contributors** HB: drafted the initial manuscript. QAD, AHS: guided patient management decisions, reviewed the manuscript. AK: reviewed and revised the manuscript for critically important intellectual content.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


